These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17205654)

  • 1. Anti-HIV agents. Maraviroc in treatment-experienced PHAs.
    TreatmentUpdate; 2006; 18(4):5. PubMed ID: 17205654
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. Maraviroc--absorption and drug-interaction issues.
    TreatmentUpdate; 2007; 19(3):5. PubMed ID: 17571441
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment. Maraviroc dosing not effective in half of blacks.
    AIDS Policy Law; 2014 Oct; 29(11):1. PubMed ID: 25330547
    [No Abstract]   [Full Text] [Related]  

  • 4. It's official...but not infallible.
    Prescrire Int; 2010 Nov; 19(110):244. PubMed ID: 21284352
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel HIV treatment approved.
    Groeschen HM
    Am J Health Syst Pharm; 2007 Sep; 64(18):1886. PubMed ID: 17823091
    [No Abstract]   [Full Text] [Related]  

  • 6. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HIV agents. Access to maraviroc.
    TreatmentUpdate; 2007; 19(3):5-6. PubMed ID: 17575574
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-HIV agents. Maraviroc and resistance.
    TreatmentUpdate; 2007; 19(6):4-5. PubMed ID: 18041148
    [No Abstract]   [Full Text] [Related]  

  • 9. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 10. More data on maraviroc in treatment-experienced patients.
    AIDS Patient Care STDS; 2007 May; 21(5):366-7. PubMed ID: 17549810
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-HIV agents. One year clinical trial results with maraviroc.
    TreatmentUpdate; 2007; 19(6):3-4. PubMed ID: 18041147
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Using maraviroc in first-line therapy.
    TreatmentUpdate; 2007; 19(6):5-6. PubMed ID: 18041149
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Maraviroc approved in Canada.
    TreatmentUpdate; 2007; 19(6):1-3. PubMed ID: 18041146
    [No Abstract]   [Full Text] [Related]  

  • 14. Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
    Moyle G; Rajicic N; Goodrich J; Mayer H; Valdez H
    AIDS; 2009 Jul; 23(12):1613. PubMed ID: 19622911
    [No Abstract]   [Full Text] [Related]  

  • 15. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
    Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
    J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory effect of maraviroc in an HIV-infected patient with concomitant myositis: a case report.
    Capetti AF; Pocaterra D; Zucchi P; Carenzi L; Rizzardini G
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(4):201-2. PubMed ID: 20798399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.
    Delobel P; Raymond S; Mavigner M; Cazabat M; Alvarez M; Marchou B; Massip P; Izopet J
    AIDS; 2010 Jun; 24(9):1382-4. PubMed ID: 20559045
    [No Abstract]   [Full Text] [Related]  

  • 20. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.